AZD-0171
- Generic Name
- AZD-0171
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: Pemetrexed/CisplatinDrug: Pemetrexed/CarboplatinDrug: Carboplatin/Paclitaxel
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 630
- Registration Number
- NCT05061550
- Locations
- 🇹🇷
Research Site, Izmir, Turkey
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
Phase 2
Active, not recruiting
- Conditions
- Locally Advanced or Metastatic Solid Tumours
- Interventions
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 126
- Registration Number
- NCT04999969
- Locations
- 🇪🇸
Research Site, Pamplona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath